Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $41.00 at The Goldman Sachs Group

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price lifted by The Goldman Sachs Group from $36.00 to $41.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other analysts also recently issued reports on the stock. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS traded down $1.82 during trading hours on Friday, reaching $44.83. The stock had a trading volume of 1,950,213 shares, compared to its average volume of 732,193. The stock has a fifty day moving average of $37.84 and a 200 day moving average of $32.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03. The stock has a market cap of $1.71 billion, a P/E ratio of -11.77 and a beta of 1.00. Tarsus Pharmaceuticals has a 52-week low of $15.60 and a 52-week high of $52.99.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $28,904,000. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Tarsus Pharmaceuticals by 1,113.5% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after purchasing an additional 824,000 shares during the period. Jennison Associates LLC increased its position in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Tarsus Pharmaceuticals during the 1st quarter worth $12,640,000. Finally, Millennium Management LLC raised its position in Tarsus Pharmaceuticals by 1,259.3% during the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after purchasing an additional 322,942 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.